The reactivity of MIB1 antibody on routinely processed paraffin sections was compared with that of Ki-67 antibody on frozen sections of 80 transitional cell carcinomas of the bladder. The percentage of labelled cells was expressed as the labelling index. MIB1 labelling indices were higher than those of Ki-67 but for each case the two values were strongly correlated (r = 0.91). Ki-67 and MIB1 indices were also correlated to tumour grade and stage (P < or = 0.001). MIB1 indices determined after both formaldehyde and ethanol based Bouin's fluid fixatives did not show any significant difference. MIB1 antibody staining after microwave oven heating of tissue sections is a simple technique for assessing the proliferative fraction of bladder tumours on fixed material. The use of MIB1 antibody permits retrospective studies and should determine whether the proliferation index in bladder carcinoma has the same prognostic value as demonstrated in other types of neoplasms.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2559.1994.tb01375.xDOI Listing

Publication Analysis

Top Keywords

mib1 antibody
12
assessing proliferative
8
bladder carcinoma
8
ki-67 antibody
8
mib1 indices
8
mib1
7
antibody
6
mib1 monoclonal
4
monoclonal antibody
4
antibody assessing
4

Similar Publications

Unlabelled: QUESTIONS AND RECOMMENDATIONS FROM THE PRIOR VERSION OF THESE GUIDELINES WITHOUT CHANGE: TARGET POPULATION: Adult patients (age ≥ 18 years) who have suspected low-grade diffuse glioma.

Question: What are the optimal neuropathological techniques to diagnose low-grade diffuse glioma in the adult?

Recommendation: Level I Histopathological analysis of a representative surgical sample of the lesion should be used to provide the diagnosis of low-grade diffuse glioma. Level III Both frozen section and cytopathologic/smear evaluation should be used to aid the intra-operative assessment of low-grade diffuse glioma diagnosis.

View Article and Find Full Text PDF

P53 and Ki67 Biomarkers are Predictors for Malignant Transformation in Oral Submucous Fibrosis: A Prospective Study.

Asian Pac J Cancer Prev

December 2024

Department of Periodontology, HKDET'S Dental College, Hospital and Reaserch Institute, Humnadad, Karnataka, India.

Objectives: Oral submucous fibrosis (OSMF) is a potentially malignant disorder (PMD) characterized by a high rate of malignant transformation (MT). OSMF exhibits atrophic epithelium yet has a high proliferation rate. Both p53 and Ki67 are nuclear proteins associated with cell proliferation, detectable in the early stages of oral cancer (OC).

View Article and Find Full Text PDF

The combined assessment of p16 and Mib/Ki-67 in oral squamous cell carcinoma.

Front Oncol

November 2024

Department of Oral and Maxillofacial Surgery, Fachklinik Hornheide, Münster, Germany.

Objective: Despite numerous studies addressing the impact of p16 in oral squamous cell carcinoma (OSCC), consistent data regarding survival and tumor proliferation behavior are lacking. Although some authors investigate both p16 and Mib/Ki-67 in their cohorts, direct correlations are consistently missing. The aim of this study was to investigate the combined influence of p16 and Mib/Ki-67 status on prognosis in OSCC.

View Article and Find Full Text PDF
Article Synopsis
  • MIB-1, a monoclonal antibody used for staining in the diagnosis of hyalinising trabecular tumor (HTT), faces challenges with manual staining methods that can lead to inconsistencies and false negatives.
  • This study aimed to evaluate if modern automated staining platforms could replicate the traditional staining patterns seen in HTT and assess how different conditions affect staining efficiency.
  • Results showed that while the Dako Autostainer Link 48 was the most stable option, other platforms like BenchMark ULTRA and Dako Omnis successfully reproduced the necessary staining under specific conditions, highlighting their potential for clinical use.
View Article and Find Full Text PDF

Background: Rheumatological toxicity associated with immunotherapy, particularly Sjögren's syndrome (SjS), has been observed with variable incidence in patients treated with immune checkpoint inhibitors (ICIs). Although SjS is a well-known autoimmune disease, its occurrence as an immune-related adverse event (irAE) during cancer treatment is less well understood. Current literature documents a range of incidence rates and clinical manifestations of SjS in patients undergoing ICI therapy, highlighting the need for early diagnosis and multidisciplinary management.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!